Immune checkpoint drugs plus chidamide for HIV cure study
Treatments studied
Part of Infections clinical trials.
This study tests whether combining immune checkpoint inhibitors with chidamide can help achieve a functional cure for HIV. It is for people living with HIV who are already on effective antiretroviral therapy and have a stable, well-controlled viral load.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must be HIV-positive and on antiretroviral therapy for at least 2 years
- Your viral load must be very low (under 50 copies/ml) for at least 12 months
- Your CD4 count must be 350 or higher
- You must be generally healthy with a BMI between 18 and 35
- You must agree to use contraception during the study and for 6 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether UB-421 combined with chidamide can shrink or control the “HIV reservoir,” the hidden HIV in the body that standard treatment may not fully eliminate. It’s mainly for people already on stable HIV medicines with very well-controlled viral levels.
This trial tests a combination of two experimental drugs designed to 'shock and kill' hidden HIV in your body. It is for people with HIV-1 subtype B who are on successful ART and want to explore a potential step toward a cure.
This trial tests a combination of two drugs that may 'wake up' hidden HIV in your body's cells, so that your immune system or other treatments can then eliminate it. The goal is to shrink the HIV reservoir that remains even when you're on antiretroviral therapy.
This trial tests a new combination of three medications, lenacapavir, teropavimab, and zinlirvimab, for people with HIV who currently have undetectable virus levels on a stable oral treatment. The goal is to see if these drugs can keep the virus suppressed, possibly allowing a simpler treatment plan.
This trial tests if two drugs, baricitinib and sirolimus, can help control HIV after stopping standard antiretroviral therapy (ART). It aims to see if these immune treatments allow patients to maintain viral suppression without daily pills.
This early-stage trial tests whether two drugs work together to reduce hidden HIV in your body while you're on stable HIV treatment. The goal is to understand how safe the combination is and whether it helps clear dormant HIV cells.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.